Skip to main content
PMC home page
British Journal of Pharmacology and Chemotherapy logoLink to British Journal of Pharmacology and Chemotherapy
. 1968 Jun;33(2):287–303. doi: 10.1111/j.1476-5381.1968.tb00990.x

The mechanism of the augmentation of responses to indirectly acting sympathomimetic amines by monoamine oxidase inhibitors.

M J Rand, F R Trinker
PMCID: PMC1570221  PMID: 5664149

Full text

PDF
287

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ASATOOR A. M., GALMAN B. R., JOHNSON J. R., MILNE M. D. THE EXCRETION OF DEXAMPHETAMINE AND ITS DERIVATIVES. Br J Pharmacol Chemother. 1965 Feb;24:293–300. doi: 10.1111/j.1476-5381.1965.tb02105.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. ASATOOR A. M., LEVI A. J., MILNE M. D. TRANYLCYPROMINE AND CHEESE. Lancet. 1963 Oct 5;2(7310):733–734. doi: 10.1016/s0140-6736(63)90368-4. [DOI] [PubMed] [Google Scholar]
  3. AXELROD J. Metabolism of epinephrine and other sympathomimetic amines. Physiol Rev. 1959 Oct;39:751–776. doi: 10.1152/physrev.1959.39.4.751. [DOI] [PubMed] [Google Scholar]
  4. AXELROD J., REICHENTHAL J., BRODIE B. B. Mechanism of the potentiating action of beta-diethylaminoethyl diphenylpropylacetate. J Pharmacol Exp Ther. 1954 Sep;112(1):49–54. [PubMed] [Google Scholar]
  5. AXELROD J. Studies on sympathomimetic amines. II. The biotransformation and physiological disposition of d-amphetamine, d-p-hydroxyamphetamine and d-methamphetamine. J Pharmacol Exp Ther. 1954 Mar;110(3):315–326. [PubMed] [Google Scholar]
  6. AXELROD J. The enzymatic deamination of amphetamine (benzedrine). J Biol Chem. 1955 Jun;214(2):753–763. [PubMed] [Google Scholar]
  7. BLACKWELL B. HYPERTENSIVE CRISIS DUE TO MONOAMINE-OXIDASE INHIBITORS. Lancet. 1963 Oct 26;2(7313):849–850. doi: 10.1016/s0140-6736(63)92743-0. [DOI] [PubMed] [Google Scholar]
  8. BLASCHKO H. Amine oxidase and amine metabolism. Pharmacol Rev. 1952 Dec;4(4):415–458. [PubMed] [Google Scholar]
  9. BRODIE B. B., GILLETTE J. R., LA DU B. N. Enzymatic metabolism of drugs and other foreign compounds. Annu Rev Biochem. 1958;27(3):427–454. doi: 10.1146/annurev.bi.27.070158.002235. [DOI] [PubMed] [Google Scholar]
  10. BRODIE B. B. Pathways of drug metabolism. J Pharm Pharmacol. 1956 Jan;8(1):1–17. doi: 10.1111/j.2042-7158.1956.tb12123.x. [DOI] [PubMed] [Google Scholar]
  11. BURKARD W. P., GEY K. F., PLETSCHER A. Differentiation of monoamine oxidase and diamine oxidase. Biochem Pharmacol. 1962 Mar;11:177–182. doi: 10.1016/0006-2952(62)90071-0. [DOI] [PubMed] [Google Scholar]
  12. BURKARD W. P., GEY K. F., PLETSCHER A. Inhibition of diamine oxidase in vivo by hydrazine derivatives. Biochem Pharmacol. 1960 Jul;3:249–255. doi: 10.1016/0006-2952(60)90088-5. [DOI] [PubMed] [Google Scholar]
  13. BURN J. H., RAND M. J. The action of sympathomimetic amines in animals treated with reserpine. J Physiol. 1958 Dec 4;144(2):314–336. doi: 10.1113/jphysiol.1958.sp006104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. CARLSSON A., LINDQVIST M. In-vivo decarboxylation of alpha-methyl DOPA and alpha-methyl metatyrosine. Acta Physiol Scand. 1962 Jan;54:87–94. doi: 10.1111/j.1748-1716.1962.tb02331.x. [DOI] [PubMed] [Google Scholar]
  15. CROUT J. R., CREVELING C. R., UDENFRIEND S. Norepinephrine metabolism in rat brain and heart. J Pharmacol Exp Ther. 1961 Jun;132:269–277. [PubMed] [Google Scholar]
  16. CROUT J. R. Effect of inhibiting both catechol-O-methyl transferase and monoamine oxidase on cardiovascular responses to norepinephrine. Proc Soc Exp Biol Med. 1961 Nov;108:482–484. doi: 10.3181/00379727-108-26972. [DOI] [PubMed] [Google Scholar]
  17. Clineschmidt V., Horita A. Auto-potentiation and potentiation by inhibition of monoamine oxidase of the sympathomimetic action of phenelzine and pheniprazine. Br J Pharmacol Chemother. 1967 May;30(1):67–77. doi: 10.1111/j.1476-5381.1967.tb02113.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. DAVEY M. J., FARMER J. B., REINERT H. The effects of nialamide on adrenergic functions. Br J Pharmacol Chemother. 1963 Feb;20:121–134. doi: 10.1111/j.1476-5381.1963.tb01303.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. DAY M. D., RAND M. J. SOME OBSERVATIONS ON THE PHARMACOLOGY OF ALPHA-METHYLDOPA. Br J Pharmacol Chemother. 1964 Feb;22:72–86. doi: 10.1111/j.1476-5381.1964.tb01545.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. DAY M. D., RAND M. J. TACHYPHYLAXIS TO SOME SYMPATHOMIMETIC AMINES IN RELATION TO MONOAMINE OXIDASE. Br J Pharmacol Chemother. 1963 Aug;21:84–96. doi: 10.1111/j.1476-5381.1963.tb01504.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Dring L. G., Smith R. L., Williams R. T. The fate of amphetamine in man and other mammals. J Pharm Pharmacol. 1966 Jun;18(6):402–404. doi: 10.1111/j.2042-7158.1966.tb07896.x. [DOI] [PubMed] [Google Scholar]
  22. Elis J., Laurence D. R., Mattie H., Prichard B. N. Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure. Br Med J. 1967 Apr 8;2(5544):75–78. doi: 10.1136/bmj.2.5544.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ellison T., Gutzait L., Van Loon E. J. The comparative metabolism of d-amphetamine-C14 in the rat, dog and monkey. J Pharmacol Exp Ther. 1966 Jun;152(3):383–387. [PubMed] [Google Scholar]
  24. FOUTS J. R., BRODIE B. B. Inhibition of drug metabolic pathways by the potentiating agent, 2, 4-dichloro-6-phenyl-phenoxyethyl diethylamine. J Pharmacol Exp Ther. 1955 Sep;115(1):68–73. [PubMed] [Google Scholar]
  25. FOUTS J. R., BRODIE B. B. On the mechanism of drug potentiation by iproniazid (2-isopropyl-1-isonicotinyl hydrazine). J Pharmacol Exp Ther. 1956 Apr;116(4):480–485. [PubMed] [Google Scholar]
  26. GANROT P. O., ROSENGREN E., GOTTFRIES C. G. Effect of iproniazid on monoamines and monamine oxidase in human brain. Experientia. 1962 Jun 15;18:260–261. doi: 10.1007/BF02148219. [DOI] [PubMed] [Google Scholar]
  27. GEY K. F., PLETSCHER A., BURKARD W. Effect of inhibitors of monoamine oxidase on various enzymes and on the storage of monoamines. Ann N Y Acad Sci. 1963 Jul 8;107:1147–1151. doi: 10.1111/j.1749-6632.1963.tb13357.x. [DOI] [PubMed] [Google Scholar]
  28. GOLDBERG L. I., DACOSTA F. M., OZAKI M. Actions of the decarboxylase inhibitor, alpha-methyl-3,4-dihydroxyphenylalanine, in the dog. Nature. 1960 Nov 5;188:502–504. doi: 10.1038/188502a0. [DOI] [PubMed] [Google Scholar]
  29. GOLDBERG L. I. MONOAMINE OXIDASE INHIBITORS. ADVERSE REACTIONS AND POSSIBLE MECHANISMS. JAMA. 1964 Nov 2;190:456–462. [PubMed] [Google Scholar]
  30. GOLDBERG N. D., SHIDEMAN F. E. Species differences in the cardiac effects of a monoamine oxidase inhibitor. J Pharmacol Exp Ther. 1962 May;136:142–151. [PubMed] [Google Scholar]
  31. GRIESEMER E. C., BARSKY J., DRAGSTEDT C. A., WELLS J. A., ZELLER E. A. Potentiating effect of iproniazid on the pharmacological action of sympathomimetic amines. Proc Soc Exp Biol Med. 1953 Dec;84(3):699–701. doi: 10.3181/00379727-84-20757. [DOI] [PubMed] [Google Scholar]
  32. HODGE J. V., NYE E. R., EMERSON G. W. MONOAMINE-OXIDASE INHIBITORS, BROAD BEANS, AND HYPERTENSION. Lancet. 1964 May 16;1(7342):1108–1108. doi: 10.1016/s0140-6736(64)91316-9. [DOI] [PubMed] [Google Scholar]
  33. HORWITZ D., LOVENBERG W., ENGELMAN K., SJOERDSMA A. MONOAMINE OXIDASE INHIBITORS, TYRAMINE, AND CHESSE. JAMA. 1964 Jun 29;188:1108–1110. doi: 10.1001/jama.1964.03060390010002. [DOI] [PubMed] [Google Scholar]
  34. KATO R., CHIESARA E., VASSANELLI P. FURTHER STUDIES ON THE INHIBITION AND STIMULATION OF MICROSOMAL DRUG METABOLIZING ENZYMES OF RAT LIVER BY VARIOUS COMPOUNDS. Biochem Pharmacol. 1964 Jan;13:69–83. doi: 10.1016/0006-2952(64)90080-2. [DOI] [PubMed] [Google Scholar]
  35. KOPIN I. J., AXELROD J., GORDON E. The metabolic fate of H3-epinephrine and C14-metanephrine in the rat. J Biol Chem. 1961 Jul;236:2109–2113. [PubMed] [Google Scholar]
  36. KOPIN I. J., AXELROD J. The role of monoamine oxidase in the release and metabolism of norepinephrine. Ann N Y Acad Sci. 1963 Jul 8;107:848–855. doi: 10.1111/j.1749-6632.1963.tb13328.x. [DOI] [PubMed] [Google Scholar]
  37. KOPIN I. J., GORDON E. K. Metabolism of administered and drug-released norepinephrine-7-H3 in the rat. J Pharmacol Exp Ther. 1963 May;140:207–216. [PubMed] [Google Scholar]
  38. KOPIN I. J., HERTTING G., GORDON E. K. Fate of norepinephrine-H3 in the isolated perfused rat heart. J Pharmacol Exp Ther. 1962 Oct;138:34–40. [PubMed] [Google Scholar]
  39. KOPIN I. J. STORAGE AND METABOLISM OF CATECHOLAMINES: THE ROLE OF MONOAMINE OXIDASE. Pharmacol Rev. 1964 Jun;16:179–191. [PubMed] [Google Scholar]
  40. MAITRE L., STAEHELIN M. EFFECT OF ALPHA-METHYL-DOPA ON MYOCARDIAL CATECHOLAMINES. Experientia. 1963 Nov 15;19:573–575. doi: 10.1007/BF02150996. [DOI] [PubMed] [Google Scholar]
  41. MALING H. M., HIGHMAN B., SPECTOR S. Neurologic, neuropathologic, and neurochemical effects of prolonged administration of phenylisopropylhydrazine (JB 516), phenylisobutylhydrazine (JB 835), and other monoamine oxidase inhibitors. J Pharmacol Exp Ther. 1962 Sep;137:334–343. [PubMed] [Google Scholar]
  42. MCEWEN L. M. The effect on the isolated rabbit heart of vagal stimulation and its modification by cocaine, hexamethonium and ouabain. J Physiol. 1956 Mar 28;131(3):678–689. doi: 10.1113/jphysiol.1956.sp005493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. MUSCHOLL E., MAITRE L. RELEASE BY SYMPATHETIC STIMULATION OF ALPHA-METHYLNORADRENALINE STORED IN THE HEART AFTER ADMINISTRATION OF ALPHA-METHYLDOPA. Experientia. 1963 Dec 15;19:658–659. doi: 10.1007/BF02151307. [DOI] [PubMed] [Google Scholar]
  44. Muscholl E. Autonomic nervous system: newer mechanisms of adrenergic blockade. Annu Rev Pharmacol. 1966;6:107–128. doi: 10.1146/annurev.pa.06.040166.000543. [DOI] [PubMed] [Google Scholar]
  45. Muscholl E. Modification of sympathetic function. Indirectly acting sympathomimetic amines. Pharmacol Rev. 1966 Mar;18(1):551–559. [PubMed] [Google Scholar]
  46. PLETSCHER A., PELLMONT B. Biochemical and pharmacologic actions of marsilid on the heart. J Clin Exp Psychopathol. 1958 Apr-Jun;19(2 Suppl 1):163–168. [PubMed] [Google Scholar]
  47. SHORE P. A., BUSFIELD D., ALPERS H. S. BINDING AND RELEASE OF METARAMINOL: MECHANISM OF NOREPINEPHRINE DEPLETION BY ALPHA-METHYL-M-TYROSINE AND RELATED AGENTS. J Pharmacol Exp Ther. 1964 Nov;146:194–199. [PubMed] [Google Scholar]
  48. SHORE P. A., COHN V. H., Jr Comparative effects of monoamine oxidase inhibitors on monoamine oxidase and diamine oxidase. Biochem Pharmacol. 1960 Oct;5:91–95. doi: 10.1016/0006-2952(60)90012-5. [DOI] [PubMed] [Google Scholar]
  49. SPECTOR S. Monoamine oxidase in control of brain serotonin and norepinephrine content. Ann N Y Acad Sci. 1963 Jul 8;107:856–864. doi: 10.1111/j.1749-6632.1963.tb13329.x. [DOI] [PubMed] [Google Scholar]
  50. SPECTOR S., SHORE P. A., BRODIE B. B. Biochemical and pharmacological effects of the monoamine oxidase inhibitors, iproniazid, 1-phenyl-2-hydrazinopropane (JB 516) and 1-phenyl-3-hydrazinobutane (JB 835). J Pharmacol Exp Ther. 1960 Jan;128:15–21. [PubMed] [Google Scholar]
  51. STONE C. A., ROSS C. A., WENGER H. C., LUDDEN C. T., BLESSING J. A., TOTARO J. A., PORTER C. C. Effect of alpha-methyl-3,4-dihydroxyphenylalanine (methyldopa), reserpine and related agents on some vascular responses in the dog. J Pharmacol Exp Ther. 1962 Apr;136:80–88. [PubMed] [Google Scholar]
  52. Smith C. B. The role of monoamine oxidase in the intraneuronal metabolism of norepinephrine released by indirectly-acting sympathomimetic amines or by adrenergic nerve stimulation. J Pharmacol Exp Ther. 1966 Feb;151(2):207–220. [PubMed] [Google Scholar]
  53. TRENDELENBURG U., MUSKUS A., FLEMING W. W., GOMEZ ALONSO de la SIERRA B. Modification by reserpine of the action of sympathomimetic amines in spinal cats; a classification of sympathomimetic amines. J Pharmacol Exp Ther. 1962 Nov;138:170–180. [PubMed] [Google Scholar]
  54. Trinker F. R., Fearn H., McCulloch M. W., Rand M. J. Experimental observations on the effects of adrenaline after treatment with antidepressant monoamine oxidase inhibitor (MAOI) drugs. Aust Dent J. 1967 Aug;12(4):297–303. doi: 10.1111/j.1834-7819.1967.tb02204.x. [DOI] [PubMed] [Google Scholar]
  55. VANOV S. Effect of monoamine oxidase inhibitors and pyrogallol on the pressor response to adrenaline, noradrenaline, normetanephrine and tyramine in the rat. Arch Int Pharmacodyn Ther. 1962 Jul 1;138:51–61. [PubMed] [Google Scholar]
  56. VOGT M. The concentration of sympathin in different parts of the central nervous system under normal conditions and after the administration of drugs. J Physiol. 1954 Mar 29;123(3):451–481. doi: 10.1113/jphysiol.1954.sp005064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. WESTERMANN E., STOCK K. [Experimental animal research on the mechanism of the narcosis-shortening action of monoamine oxidase inhibitors]. Chemotherapia (Basel) 1962;4:329–339. [PubMed] [Google Scholar]
  58. WIEGAND R. G., PERRY J. E. Effect of L-DOPA and N-methyl-N-benzyl-2-propynylamine. HC1 on DOPA, dopamine, norepinephrine, epinephrine and serotonin levels in mouse brain. Biochem Pharmacol. 1961 Aug;7:181–186. doi: 10.1016/0006-2952(61)90084-3. [DOI] [PubMed] [Google Scholar]
  59. WITT P. N., BRETTSCHNEIDER L., BORIS A. P. Sensitivity to D-amphetamine in spiders after iproniazid and imipramine. J Pharmacol Exp Ther. 1961 May;132:183–192. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology and Chemotherapy are provided here courtesy of The British Pharmacological Society

RESOURCES